NanoViricides, Inc. (NYSE American: NNVC) stated that the current severe influenza wave underscores the urgent need for broad-spectrum antiviral therapies capable of addressing influenza, RSV, coronaviruses and other respiratory viruses. The company cited limitations of seasonal vaccines and existing antivirals that face timing constraints and resistance risks.
The company highlighted its Phase II-stage drug candidate NV-387, a broad-spectrum nanoviricide designed to mimic host-cell features viruses rely on to infect cells. Management believes this positions NV-387 as a potential first-line, empirical therapy for viral acute and severe acute respiratory infections. The drug candidate has demonstrated preclinical activity against influenza, RSV and coronaviruses and has potential applicability across a multibillion-dollar global antiviral market if approved.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections.
The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
NV-387 is planned for development as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NanoViricides is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company's platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel.
NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of numerous human viral diseases. The company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital.
As with any drug development efforts by any company, there can be no assurance at this time that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in the company's lab will lead to successful clinical trials or a successful pharmaceutical product. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
